Drug Profile
AZD 5658
Alternative Names: AZD5658Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-I for Obesity in USA (PO)
- 28 Jul 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 27 Jan 2011 Phase-I clinical trials in Obesity in USA (PO)